“The purely physical mode of action of Lactobacillus johnsonii EU1 is scientifically proven and has another advantage,” explains Dr Guido Middeler, Diapharm’s probiotic expert. “The medical device has a clear medical intended purpose for the prophylaxis and, chiefly, the treatment of symptoms – similar to medicinal products.” In addition, he states, it closes the gap created by negative EFSA assessments of the health claims of dietary supplements including probiotics: “With Lactobacillus johnsonii EU1 as a medical device, distributors can avoid this gap and round off their brand portfolio,” Dr Guido Middeler states confidently.
For more information, please contact Nicole Sibbing, Diapharm GmbH & Co. KG (Tel.: +49 251-60935-0, email: nicole.sibbing(at)diapharm.com).
(approx. 1,380 characters)